Creating and developing innovative therapies

Deborah RathjenCEO & Managing Director

For

per

sona

l use

onl

y

Safe Harbor Statement

Factors Affecting Future PerformanceThis presentation contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ development candidates BNC105, BNC210 (IW-2143), BNC101(ET101) and BNC375, its licensing agreements with Ironwood Pharmaceuticals and Merck & Co, its acquisition of Eclipse Therapeutics, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

2

For

per

sona

l use

onl

y

Bionomics Snapshot

KEY STATISTICS (July 2013)

ASX code BNO

Share price (26/7/13) A$0.40

52 week high A$0.455

52 week low A$0.245

Shares on issue 411.1M

Market capitalisation A$164M

Cash 30/6/13 A$22.5M

MANAGEMENT

Deborah Rathjen CEO & MD

José Iglesias CMO

Melanie Young CFO & Company Secretary

3

BOARD

Graeme Kaufman Chairman

Deborah Rathjen CEO & MD

Trevor Tappenden Non-exec Director

Errol DeSouza Non-exec Director

Jonathan Lim Non-exec Director

6 MONTH SHARE PRICE PERFORMANCE

For

per

sona

l use

onl

y

Emerging biotech with global operations in Australia (ASX:BNO), Europe and the United States

World class discovery and development capabilities targeting multi-billion dollar market opportunities in solid tumour oncology, CNS, and immune diseases

Broad and deep portfolio of clinical and preclinical drug candidates supported by proprietary technology platforms:

BNC105 solid tumour targeting agent in Phase II trials for renal and ovarian cancer with key data in early 2014

BNC210 (IW-2143) targeting anxiety and depression partnered with Ironwood Pharmaceuticals

US$345 million in upfront, research and milestone payments, plus royalties

BNC101 and other Cancer Stem Cell (CSC) targeting antibodies from the acquisition of Eclipse Therapeutics; BNC101 entering clinic in 2014

Nav1.7 program targeting chronic and neuropathic pain partnered with Merck & Co (MSD)

US$172 million in option exercise fees, development and regulatory milestone payments, plus royalties

Partnerable Kv1.3 program and BNC375 drug candidate anticipated to generate additional value inflection points in CY2013

Strategy to partner our compounds at key value points to crystallise value, improve rate of success and manage risk

4

Bionomics Investment HighlightsF

or p

erso

nal u

se o

nly

Bionomics Business Model

Partnering is key to managing execution risk, validating our compounds and ensuring our

compounds reach their markets

5

Drug Discovery

Drug Development Partnering

• Lay off risk with experienced partners

• Generate revenue streams to support discovery programs 

• Platform for delivering new drug candidates

• Propagates pipeline with multiple shots on goal

• Targeted clinical trials 

For

per

sona

l use

onl

y

DRUG CANDIDATE/PROGRAM DISCOVERY PRE-CLINICAL PHASE I PHASE II LICENSEE/

PARTNER

CANCER

BNC105 – Solid Tumours, renal, ovarian, mesothelioma

BNC101 – Cancer stem cells, Solid Tumours, colon, breast, pancreatic

BNC102 – Cancer stem cells, Solid Tumours

VEGFR3 – Solid Tumours, melanoma, breast

RET – lung and thyroid Cancers

CENTRALNERVOUSSYSTEM

BNC210 (IW-2143) – Anxiety/Depression

BNC375 – Cognitive impairment, Alzheimer's Disease, ADHD, schizophrenia

GABA-A – Epilepsy

NaV1.7 - Pain

IMMUNE DISEASE

Kv1.3 –Psoriasis, Multiple Sclerosis, Rheumatoid Arthritis

Drug Candidate Portfolio Leverages Core Strengths

6

CORE STRENGTHS

Targeted licensing point

For

per

sona

l use

onl

y

Nav 1.7: $172M Pain Partnership with Merck & Co

7

COMMERCIAL ELEMENTS

Option and license agreement with Merck & Co US$172m in option exercise fees, development/regulatory milestone

payments, plus royalties

THERAPEUTIC AREA Treatment of chronic pain, including neuropathic pain

MARKET SIZE &

POSITIONING

Pain Market totalled US$22 billion in sales in 2010 Neuropathic pain segment of market expected to grow from US$2.4

billion in 2010 to US$3.6 billion by 2020 Current medications have limited effectiveness:

estimated only 1 in 4 patients with neuropathic pain achieve >50% reduction in pain levels

side-effects include drowziness, somnolence and dizziness

VALIDATION Nav1.7 as a target has been validated through genetic studies

Deal further validates ionX & MultiCore drug discovery platforms Value creation through strategic partnering business model Future success-based revenue streams & royalties secured

For

per

sona

l use

onl

y

BNC210 (IW-2143): A next generation compound with potential in the treatment of anxiety and depression

TREATMENT Anxiety and Depression

MODE OF ACTION

Modulates novel pathway, to promote anti-anxiety activity and neuriteoutgrowth in vitro.

CLINICAL

Four Phase I trials completed, including a trial assessing panic attack symptoms:

59 subjects enrolled in double-blinded placebo controlled trial;15 subjects classified as having a panic attack upon CCK-4 administration Statistically significant decrease in both number & intensity of

symptoms (p<0.05) BNC210 treated subjects returned to normal emotional status within

10 minutes, compared to 60 minutes on placebo This trend correlated with the statistically significant reduction in

panic symptoms by BNC210 BNC210 has been administered to 108 healthy subjects to date with

excellent safety profile

BENEFITS BNC210-related changes in human brain activity indicative of efficacy Reduced panic symptoms No evidence of sedation or addiction to date

MARKETS

Anxiety – global sales of US$5-7bn annually Depression – global sales US$11bn Partnered with Ironwood (NASDAQ:IRWD) US$345 million in upfront,

research and milestone payments, plus royalties

8

For

per

sona

l use

onl

y

COMPETITIVE ADVANTAGES OF BNC210*

DRUG NO SEDATION

NO WITHDRAWAL

SYNDROMENO MEMORY IMPAIRMENT

FAST ACTING

NO DRUG/DRUG INTERACTIONS

ONCE-A-DAY

DOSING

BNC210

VALIUM

PROZAC

BUSPAR

* Based on preclinical data and results of Phase I trial comparing BNC210 with Lorazepam

BNC210 (IW-2143): Fewer side-effects expected to be a key product differentiator

9

For

per

sona

l use

onl

y

7 NAChR receptor activation improves attention, working memory and recognition memory

Following late-stage development failures by drugs targeting β-amyloid (Lilly, Pfizer, J&J), 7 NAChR approaches have come to the forefront; Pharma hungry for AD drugs

Market opportunity for drugs modulating 7 NAChR activity includes many neurodegenerative and psychiatric disorders: Alzheimer’s Disease (AD), Parkinson’s Disease, Schizophrenia, ADHD and

mood and anxiety disorders

Prevalence Estimated Global sales

Alzheimer’s Disease

9.7 Million $10.2 Billion (2012)

Cognitive Dysfunction in Schizophrenia

3.4 Million No approved products

ADHD 44.9 Million $4.9 Billion

Parkinson’s Disease

7.0 Million $3.5 Billion

BNC375: More than Alzheimer’s Disease

10

For

per

sona

l use

onl

y

BNC375: Competitive advantages*

CharacteristicsBionomicsBNC375

CompetingAgents+

Potent

Rapid onset of action

Potentiates endogenous receptor ligand

Preserve the normal signalling patterns of the receptor

Do not cause receptor desensitization

No potential for development of tolerance

Selectivity over other nicotinic receptors

11

*Based on data from preclinical animal studies+Published information and Bionomics’ in-house data

For

per

sona

l use

onl

y

BNC105: “Best in Class” vascular targeting agent with unique dual mechanism of action

TREATMENT Solid Cancers: New paradigm with blockbuster potential through rational combination with molecular targeted therapies that benefit from induction of tumour hypoxia

MARKETS

The current market size in treatment of all solid tumours is >US$10b (Avastin, Genentech/Roche sales >US$5b in 2011)

Renal cancer market size >US$2.5bn; include TKI Sutent, Pfizer; Nexavar, Bayer/Onyx; Afinitor, Novartis

Ovarian cancer market size US$2.2bn in 2011

CLINCAL

Phase II Renal cell cancer (US, Australia, Singapore) Trial design: randomized 2-arm; Afinitor+/- BNC105; enrolment of 139 patients

completed; patients previously failed TKI therapy; Primary endpoint 6 month PFS; data anticipated 2H, 2013

Phase I results: combination BNC105 + Afinitor safe and well tolerated; 12 patients enrolled across 4 BNC105 dose levels (4-16mg/m2); 8 patients achieved stable disease; 1 patient still on study having received 24 treatment cycles (72 weeks, 18 months)

Phase II Mesothelioma (Australia): single arm; BNC105 following Alimta + cisplatin failure; 30 patients enrolled; 1 patient with durable & sustained partial response with corresponding reduction in mesothelin levels; 13 patients with stable disease

Phase I/II Ovarian cancer (Australia, New Zealand, US) Phase I enrolment completed; carboplatin and gemcitabine +/- BNC105; population

partially sensitive to platinum-based therapy

BENEFITS

Dual Action – selectively targets both tumour blood vessels and cancer cells

Rapid, Potent Action – works rapidly to shut down tumour blood vessels, potent anti-tumour action as a single agent, tumour less likely to escape treatment

Enhances Effectiveness of Other Cancer Treatments – delivers synergistic anti-cancer effects in numerous combinations (e.g., anti-VEGF)

12

For

per

sona

l use

onl

y

BNC105treateduntreated

13

By selectively shutting down tumour blood vessels, BNC105 rapidly inhibits tumour growth

BNC105: Targeting solid tumours F

or p

erso

nal u

se o

nly

BNC105: Renal Cancer

Phase II Trial Enrolment now complete 139 patients On pathway to partnership

Potential to be a new treatment paradigm for patients with renal cancer

Encouraging initial results from US renal cancer trial Combination of Afinitor &

BNC105 safe & well tolerated

As effective as Sutent in reducing tumour size in animal model Sutent (Pfizer) is the current

market leader with 2010 global sales US$1b

14

Right Kidney Tumour Burden

Globally, Renal Cancer is 7thmost common form of  cancer resulting in over 100,000 deaths p.a.

For

per

sona

l use

onl

y

Cancer Stem Cell Therapeutics

The missing link in treating solid tumours

CSCs are resistant to conventional therapies

Eradicating CSCs may prevent tumour recurrence

Complements the BNC105 program by targeting the “seeds” of cancer

15

For

per

sona

l use

onl

y

BNC101: Targeting cancer stem cells in solid tumours

TREATMENT Solid tumours; colon, breast, pancreaticMOA Humanised monoclonal antibody

BNC101 binds selectively to LGR5; LGR5 marks tumour-initiating cells in colon and gastric cancer

LGR5 is highly overexpressed in colon, ovarian, liver, breast, lung and other solid tumours

Ligand: R-spondin, forms part of LGR5 – LRP6 – Wnt –Fzd signaling complex

High expression of LGR5 in colon cancer has been linked to tumour recurrence and poor prognosis

MARKETS Market for cancer stem cell therapeutics has been estimated to be a $8B market opportunity by 2018

DEVELOPMENT STAGE

Late preclinical; GMP manufacture by Lonza; IND enabling studies commenced in US; Anticipated IND filing 2014

BENEFITS First-in-class therapeutic antibody against validated CSC targetSpecific targeting of cancer stem cells

16

For

per

sona

l use

onl

y

Market Opportunity: CSCs Next Significant Advance in Cancer Treatment

Company Technology Financials

OncoMed CSC antibodies targeting cancer gene/signalling pathways (Wnt & Notch)

Strong preclinical trial results Clinical trials ongoing

Strategic alliance: Bayer Total: >$1,975M Upfront: $40M

Strategic alliance: GSK Total:>$1,400M Upfront: undisclosed

IPO July 2013, raised $85M, priced $17 per share, market cap $500M

StemlineTherapeutics

Discovery Platform Phase I/II clinical trials

IPO Jan 2013 (NASDAQ:STML)

Market cap $330M

Verastem Screening platform CSC-like cells Preclinical Wnt program Clinical focal adhesion kinase (FAK) program

IPO 2012 (NASDAQ:VYST) Market cap~$330M

Boston Biomedical

Advanced clinical development programs (Phase I, II, planning Phase III)

Acquired by Dainippon for >$2.6B in 2012 ($200M upfront)

Roche(Arius)

Pre-IND anti-CD44 antibody Acquired for $184M cash by Roche

17

For

per

sona

l use

onl

y

R&D Outlook & Anticipated Milestones: Partnership Focus

Key Program Milestone Anticipated Timing (CY)

BNC105: All Solid Tumours

Complete Phase II renal cancer trial enrolment 1H, 2013Results from renal cancer trial 1Q, 2014

Complete ovarian Phase I trial enrolment 1H,2013New data presentations at AACR, ASCO-GU & ASCO 1H, 2013BNC101(formerly ET101): Cancer Stem Cells

Initiation of IND enabling studies & GMP manufacture 1H, 2013 BNC375/Alpha 7: Alzheimer’s Disease/Cognitive Enhancement

Drug candidate selection 2H, 2012 Initiation of IND enabling studies & GMP manufacture 1H, 2013

Kv1.3: Autoimmune Disease

Partnership 2013

18

Nav1.7 partnership with Merck & Co ‐ potential for up to US$172 million in option fees, regulatory and development milestones, plus royalties

For

per

sona

l use

onl

y

BNO Investment Proposition

Bionomics has world class discovery & development capabilities targeting multi-billion dollar market opportunities in cancer, CNS & immune diseases

Bionomics’ technology platforms deliver diversified product pipeline, while corporate partnering manages execution risk

Clinical trial success of BNC105 in renal cancer should lead to a lucrative licensing transaction

Licensing of anxiety drug BNC210 to Ironwood has potential to deliver significant shareholder returns via milestone payments and royalties

Latest partnership with Merck & Co (MSD) further demonstrates Bionomics’ business model

Advancing range of additional pipeline drug candidates including BNC375 Alzheimer’s candidate & Kv1.3 program with strong partnering potential

Acquisition of Eclipse Therapeutics (now Bionomics Inc) has positioned BNO as a leading player in cancer stem cells, adding high value antibody therapeutics & a US platform

Bionomics well positioned to execute its plan to build sustainable revenue streams from multiple drug candidates

19

For

per

sona

l use

onl

y

ASX:BNO

www.bionomics.com.au

20

For

per

sona

l use

onl

y